- Home
- GRF vs BTAI Comparison
GRF vs BTAI Comparison
Compare GRF & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRF | BTAI |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 35.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | GRF | BTAI |
|---|---|---|
| Price | $9.97 | $1.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 3.8K | ★ 720.0K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ 75.63 |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $197.82 |
| Revenue Next Year | N/A | $910.15 |
| P/E Ratio | $8.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.50 | $1.01 |
| 52 Week High | $11.85 | $8.08 |
Technical Indicators
Market Signals| Indicator | GRF | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 57.29 |
| Support Level | $9.96 | $1.05 |
| Resistance Level | $10.13 | $1.26 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 29.33 | 83.09 |
Price Performance
Historical ComparisonAbout GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.